Over the past decade, JNKs have increasingly been recognized as an attractive molecule target for the treatment of cancers [40] and recent studies have shown involvement of JNK activation in hepatic carcinogenesis [41-43], making JNK to be a therapeutic target of human HCC development and progression. This evidence concerns the gene MAPK8 and hepatocellular carcinoma.